$SIGA has a dividend of $.60.
Approvals:
- U.S. & Canada: Approved for treating smallpox.
- EU, UK, & Japan: Approved for a broader range of orthopoxviruses, including mpox, cowpox, and complications from smallpox vaccinations.
Stockpiling: SIGA has long-term contracts to supply TPOXX to the U.S. Strategic National Stockpile and international governments.
Latest Earnings Report (Full-Year 2025)
- Total Revenue: $94.6 million for the full year, a decrease from previous years.
- Q4 Revenue: Dropped sharply to $3.8 million, resulting in a quarterly net loss of $5.4 million (EPS: -$0.08).
- Net Income: $23.3 million for the full year.
- Earnings Per Share (EPS): $0.32 (fully diluted).
- Cash Position: Ended 2025 with $155 million in cash and zero debt.
- Dividends: Declared a $0.60 per share special cash dividend in March 2026, paid on April 23, 2026.
- Upcoming Q1 2026: Earnings are estimated to be released around May 7, 2026.
